Brought to you by 
GSK and Myogen sign two PAH agreements
21 May 2015
Executive Summary
Myogen (develops small molecules for cardiovascular diseases) licensed GlaxoSmithKline ex-US commercialization rights to the Phase III pulmonary arterial hypertension (PAH) compound ambrisentan. Concurrently, GSK has licensed Myogen US marketing and distribution rights to sell its PAH drug Flolan (epoprostenol) for three years.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com